LAVA THERAPEUTICS NV (LVTX) Stock Income Statement
NASDAQ:LVTX - Nasdaq - NL0015000AG6 - Common Stock - Currency: USD
| TTM (2024-9-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.34M | 11.98M | 6.77M | 19.39M | 5.00M | |||
| Cost Of Goods | 154.00K | 0.00 | 3.48M | N/A | N/A | |||
| Gross Profit | 7.19M | 11.98M | 3.29M | N/A | N/A | |||
| Operating Expenses | 35.23M | 41.67M | 46.68M | 54.23M | 49.35M | |||
| Research and Development | 24.20M | 28.45M | 32.56M | 40.11M | 37.19M | |||
| Selling, General, and Administrative Expenses | 11.03M | 13.22M | 14.12M | 14.12M | 12.16M | |||
| Operating Income | -28.04M | -29.69M | -43.39M | -34.84M | -44.35M | |||
| Interest Income/Expense | 708.00K | 5.21M | 1.78M | 3.18M | -840.00K | |||
| Income Before Taxes | -27.33M | -24.48M | -41.61M | -31.66M | -45.19M | |||
| Income Tax | 311.00K | 630.00K | 257.00K | 250.00K | 160.00K | |||
| Net Income | -27.64M | -25.11M | -41.87M | -31.91M | -45.35M | |||
| EBITDA | -27.00M | -29.23M | -42.78M | -34.06M | -43.79M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.02 | -0.94 | -1.57 | -1.23 | -2.30 | |||
| Non GAAP EPS | -1.03 | -0.93 | -1.59 | -1.25 | -11.12 | |||
| Statistics | ||||||||
| Gross Profit Margin | 97.90% | 100.00% | 48.56% | N/A | N/A | |||
| Profit Margin | -376.35% | -209.60% | -618.57% | -164.57% | -907.00% | |||
| Operating Profit Margin | -381.76% | -247.81% | -641.07% | -179.68% | -887.00% | |||
All data in USD